Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 1
1957 2
1967 1
1968 1
1969 3
1970 4
1971 4
1972 8
1973 6
1974 5
1975 4
1976 9
1977 7
1978 3
1979 7
1980 8
1981 14
1982 7
1983 9
1984 19
1985 34
1986 13
1987 29
1988 10
1989 12
1990 20
1991 15
1992 11
1993 18
1994 15
1995 22
1996 25
1997 27
1998 23
1999 30
2000 31
2001 34
2002 25
2003 31
2004 33
2005 32
2006 38
2007 29
2008 42
2009 31
2010 38
2011 49
2012 53
2013 57
2014 65
2015 63
2016 63
2017 81
2018 98
2019 109
2020 132
2021 106
2022 106
2023 106
2024 49

Text availability

Article attribute

Article type

Publication date

Search Results

1,686 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypotrichosis 3"
Page 1
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R. King B, et al. Lancet. 2023 May 6;401(10387):1518-1529. doi: 10.1016/S0140-6736(23)00222-2. Epub 2023 Apr 14. Lancet. 2023. PMID: 37062298 Clinical Trial.
We investigated the efficacy and safety of ritlecitinib, an oral, selective dual JAK3/TEC family kinase inhibitor, in patients with alopecia areata. METHODS: In this randomised, double-blind, multicentre, phase 2b-3 trial done at 118 sites in 18 countries, pa …
We investigated the efficacy and safety of ritlecitinib, an oral, selective dual JAK3/TEC family kinase inhibitor, in patients with alopecia …
European expert consensus statement on the systemic treatment of alopecia areata.
Rudnicka L, Arenbergerova M, Grimalt R, Ioannides D, Katoulis AC, Lazaridou E, Olszewska M, Ovcharenko YS, Piraccini BM, Prohic A, Rakowska A, Reygagne P, Richard MA, Soares RO, Starace M, Vañó-Galvan S, Waskiel-Burnat A. Rudnicka L, et al. J Eur Acad Dermatol Venereol. 2024 Apr;38(4):687-694. doi: 10.1111/jdv.19768. Epub 2024 Jan 2. J Eur Acad Dermatol Venereol. 2024. PMID: 38169088 Review.
Children and adolescents with alopecia areata often experience bullying, including physical aggression. The disease severity evaluation tools used in clinical practice are: the Severity of Alopecia Tool (SALT) score and the Alopecia Areata Scale (AAS). ...Currently, the on …
Children and adolescents with alopecia areata often experience bullying, including physical aggression. The disease severity evaluation tool …
Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss: A Systematic Review.
Drake L, Reyes-Hadsall S, Martinez J, Heinrich C, Huang K, Mostaghimi A. Drake L, et al. JAMA Dermatol. 2023 Jan 1;159(1):79-86. doi: 10.1001/jamadermatol.2022.4867. JAMA Dermatol. 2023. PMID: 36449274
Outcomes of interest were disease course, both objectively and subjectively measured. Data were evaluated from January 3 to 11, 2022. FINDINGS: The database searches yielded 6347 citations to which 11 articles from reference lists were added. Of this total, 30 articles wer …
Outcomes of interest were disease course, both objectively and subjectively measured. Data were evaluated from January 3 to 11, 2022. …
Baricitinib for the Treatment of Alopecia Areata.
Freitas E, Guttman-Yassky E, Torres T. Freitas E, et al. Drugs. 2023 Jun;83(9):761-770. doi: 10.1007/s40265-023-01873-w. Epub 2023 May 17. Drugs. 2023. PMID: 37195491 Free PMC article. Review.
AA treatment aims to stop its progression and reverse hair loss, and JAK inhibition has been shown to stop hair loss and reverse alopecia and has exhibited promising results in treating AA in clinical trials. Baricitinib, an oral, reversible, selective JAK1/JAK2 inhibitor, …
AA treatment aims to stop its progression and reverse hair loss, and JAK inhibition has been shown to stop hair loss and reverse alopecia an …
Pediatric androgenetic alopecia: A review.
Griggs J, Burroway B, Tosti A. Griggs J, et al. J Am Acad Dermatol. 2021 Nov;85(5):1267-1273. doi: 10.1016/j.jaad.2019.08.018. Epub 2019 Aug 12. J Am Acad Dermatol. 2021. PMID: 31415838 Review.
RESULTS: We identified 7 articles discussing androgenetic alopecia in patients aged younger than 18. One of these articles was a review containing data from 3 conference abstracts, which were also included in the analysis. ...
RESULTS: We identified 7 articles discussing androgenetic alopecia in patients aged younger than 18. One of these articles was a review cont …
Hair loss and herbs for treatment.
Lourith N, Kanlayavattanakul M. Lourith N, et al. J Cosmet Dermatol. 2013 Sep;12(3):210-22. doi: 10.1111/jocd.12051. J Cosmet Dermatol. 2013. PMID: 23992163 Review.
Janus kinase inhibitors for alopecia areata.
King BA, Craiglow BG. King BA, et al. J Am Acad Dermatol. 2023 Aug;89(2S):S29-S32. doi: 10.1016/j.jaad.2023.05.049. J Am Acad Dermatol. 2023. PMID: 37591562 Review.
Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and considerations regarding differences among JAK inhibitors, safety, and patient selection....
Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, an …
Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice.
Saceda-Corralo D, Moustafa F, Moreno-Arrones Ó, Jaén-Olasolo P, Vañó-Galván S, Camacho F. Saceda-Corralo D, et al. J Drugs Dermatol. 2022 Jul 1;21(7):742-747. doi: 10.36849/JDD.6610. J Drugs Dermatol. 2022. PMID: 35816059
OBJECTIVE: The main objective was to describe the safety profile of mesotherapy with dutasteride in real clinical practice in a large cohort of patients with androgenetic alopecia. ...Most of them presented clinical improvement, being a marked improvement in 33 pati …
OBJECTIVE: The main objective was to describe the safety profile of mesotherapy with dutasteride in real clinical practice in a large …
Chemotherapy, Alopecia, and Scalp Cooling Systems.
Amarillo D, de Boni D, Cuello M. Amarillo D, et al. Actas Dermosifiliogr. 2022 Mar;113(3):278-283. doi: 10.1016/j.ad.2021.09.003. Epub 2021 Oct 12. Actas Dermosifiliogr. 2022. PMID: 35526920 Free article. Review. English, Spanish.
We review the evidence on the effects and effectiveness of these systems, which are making their way into routine clinical practice....
We review the evidence on the effects and effectiveness of these systems, which are making their way into routine clinical practice.. …
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Kwon O, et al. Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1. Am J Clin Dermatol. 2023. PMID: 36855020 Free PMC article. Clinical Trial.
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of baricitinib for AA in adults with 50% scalp hair loss through 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). METHODS: Patients randomized to baricitinib at baseli …
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of baricitinib for AA in adults with 50% scalp hair loss through 52 …
1,686 results